Tradestie Institutional Equity Comparison Engine

STLN vs SABS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SABS Overall Edge

SABS Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SAB Biotherapeutics, Inc. Common Stock (SABS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, STLN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus SABS at N/M Forward P/E and 0.0% operating margin (-62.4% YoY). In options structure, STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SABS sits in CONSOLIDATION (21st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
STLN N/M vs SABS N/M Fwd P/E
Growth & Margin Winner SABS
Op Margin N/A vs 0.0% ยท YoY N/A vs -62.4%
Momentum & Technical Winner SABS
1Y -42.0% vs -26.6% ยท 52W Pos 1% vs 14%
Options & Structure Winner SABS
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (21st %ile IV)
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
1M Return -56.58%
1Y Return -41.97%
Forward P/E N/M
Unified AI Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
SABS NASDAQ
SAB Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.81
-3.44% 1D
Market Cap $262.2M
1M Return -7.57%
1Y Return -26.63%
Forward P/E N/M
Unified AI Score
37.4 / 100 SELL
Tech 20.0 Fund 52.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: STLN -41.97% SABS -26.63% Spread: +14.96 pp (SABS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
STLN TTM Op. Margin: N/A SABS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs SABS. Trailing 12-month operating profitability (STLN N/A vs SABS 0.0%) and valuation multiples (STLN N/M vs SABS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: STLN (1) vs SABS (7)
Institutional Metric STLN SABS Criterion Row Winner
Market Capitalization Scale N/A $262.2M Larger Scale SABS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A -62.4% Higher Growth SABS
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin SABS
Net Profit Margin Profitability N/A 0.0% Higher Margin SABS
Return on Equity (ROE) Capital Efficiency N/A -42.8% Higher ROE SABS
52-Week Range Position Momentum 1% ($3โ€“$7) 14% ($2โ€“$5) Stronger Trend SABS
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 175% Vol 1.38ฮฒ ยท 76% Vol Lower Realized Risk SABS
Unified Institutional Score Composite Signal 46.6 / 100 (HOLD) 37.4 / 100 (SELL) Higher Composite STLN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full STLN vs SABS Buy Guide
STLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live STLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SABS CONSOLIDATION
15d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live SABS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither STLN nor SABS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.